RhoChi Seminar Night - Oncology Pharmacy
•
1 like•414 views
Laura Bobolts discussed career opportunities in oncology pharmacy. She shared her personal journey from wanting to cure cancer as a biochemist to becoming a clinical oncology pharmacist. Her current role involves managing a team of oncology pharmacists, reviewing drug authorizations, providing therapy recommendations, and participating in sales and marketing. The job market for oncology pharmacists is strong and growing, with opportunities in hospitals, clinics, specialty pharmacies, and pharmaceutical companies. Employers seek candidates with residency training, board certification, research experience, and publications. Students are advised to gain experience through shadowing, set goals, and consider residency to prepare for a career in this field.
Report
Share
Report
Share
Download to read offline
Recommended
Oncology clinical pharmacy from practice to research
The document provides an overview of the history and current state of oncology clinical pharmacy from practice to research. It discusses how clinical pharmacists can play important roles in patient care by developing pharmaceutical care plans, managing side effects of cancer treatment, preventing and treating complications, and counseling patients. Clinical pharmacists are also involved in research by conducting clinical trials, publishing original research and reviews, and developing evidence-based guidelines. Overall, the involvement of clinical pharmacists in direct patient care and research has been shown to improve outcomes and reduce healthcare costs.
MCBS
The document discusses value assessment frameworks for cancer therapies developed by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). It describes ESMO's Magnitude of Clinical Benefit Scale (ESMO-MCBS), which provides a relative ranking of clinical benefit for new cancer drugs. Studies applying the ESMO-MCBS found that it supported treatment decisions and aligned with reimbursement decisions. While the ESMO-MCBS provides standardized benefit assessment, it only applies to comparative studies and cannot assess single-arm trials. Overall, the ESMO-MCBS provides an unbiased and standardized approach to quantify the clinical benefit of new cancer treatments.
Medication saftey oncology setting
1. Chemotherapy medication errors pose significant risks to patient safety, ranging from 0.4% to 31.9% of incidents according to literature, with around 11% causing patient harm.
2. Common chemotherapy medication errors involve administering the wrong dose or wrong drug, as well as failures during the prescribing, preparation, and administration phases.
3. Numerous guidelines and standards have been introduced over time to improve chemotherapy medication safety, including checklists, error reporting systems, education, and standardized processes.
Clinical pharmacist Managed Oncology Clinic In University Hospital
The document discusses the role and history of clinical pharmacists in managing oncology clinics. It describes how clinical pharmacists began in the 1960s and their role has expanded over the years. The main goals of clinical pharmacists are to assist physicians in prescribing and monitoring drug therapy, assist medical staff, and maximize patient compliance. Oncology pharmacists play a vital role on the healthcare team by ensuring optimal medication regimens for cancer patients, educating patients, and monitoring patients for side effects during chemotherapy treatment.
Pharmacogenomic presentation medication saftey 110417 final2
This document outlines a study on the influence of pharmacogenomics on drug therapy and personalized medicine. The study focused on analyzing gene polymorphisms related to thyroid function in the Saudi population and their association with thyroid cancer risk and thyroxine drug dose requirements. The study found several novel and common single nucleotide polymorphisms in genes like DIO1, DIO3, PAX8, TSHB, and NIS. Some of these gene variants were associated with increased thyroid cancer risk. Additionally, polymorphisms in DIO1, PAX8 and TSHB were found to predict differences in required thyroxine drug doses for patients.
Personalized medicine in pediatric cancer
The maturation of genomic technologies has enabled new
discoveries in disease pathogenesis as well as new approaches to patient care.
In pediatric oncology, patients may now receive individualized genomic analysis to identify molecular aberrations of relevance for diagnosis and/or treatment.
Several recent clinical studies have begun to explore the feasibility and utility of genomics-driven precision medicine.
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Tumor conferences are multidisciplinary meetings at which the
management of cancer patients is discussed. They have been
an integral part of oncology services and are regarded
as an essential component of quality control and continuing
medical education. There are data to suggest that the tumor conference enhances patient care. Many studies of effectiveness have been conducted. Reported benefits include improved patient management and treatment. In this presentation, I'll try to assess the role of the multidisciplinary tumor conference in patient management in gynecologic oncology services.
Use of complementary and alternative medicine by cancer patients at the Unive...
CAM use is common among cancer patients in Nigeria. Most users do not obtain the
expected benefits, and adverse events are not uncommon. Every clinician in the field of oncology
should ask his/her patients about the use of CAM; this knowledge will enable them to better
counsel the patients
Recommended
Oncology clinical pharmacy from practice to research
The document provides an overview of the history and current state of oncology clinical pharmacy from practice to research. It discusses how clinical pharmacists can play important roles in patient care by developing pharmaceutical care plans, managing side effects of cancer treatment, preventing and treating complications, and counseling patients. Clinical pharmacists are also involved in research by conducting clinical trials, publishing original research and reviews, and developing evidence-based guidelines. Overall, the involvement of clinical pharmacists in direct patient care and research has been shown to improve outcomes and reduce healthcare costs.
MCBS
The document discusses value assessment frameworks for cancer therapies developed by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). It describes ESMO's Magnitude of Clinical Benefit Scale (ESMO-MCBS), which provides a relative ranking of clinical benefit for new cancer drugs. Studies applying the ESMO-MCBS found that it supported treatment decisions and aligned with reimbursement decisions. While the ESMO-MCBS provides standardized benefit assessment, it only applies to comparative studies and cannot assess single-arm trials. Overall, the ESMO-MCBS provides an unbiased and standardized approach to quantify the clinical benefit of new cancer treatments.
Medication saftey oncology setting
1. Chemotherapy medication errors pose significant risks to patient safety, ranging from 0.4% to 31.9% of incidents according to literature, with around 11% causing patient harm.
2. Common chemotherapy medication errors involve administering the wrong dose or wrong drug, as well as failures during the prescribing, preparation, and administration phases.
3. Numerous guidelines and standards have been introduced over time to improve chemotherapy medication safety, including checklists, error reporting systems, education, and standardized processes.
Clinical pharmacist Managed Oncology Clinic In University Hospital
The document discusses the role and history of clinical pharmacists in managing oncology clinics. It describes how clinical pharmacists began in the 1960s and their role has expanded over the years. The main goals of clinical pharmacists are to assist physicians in prescribing and monitoring drug therapy, assist medical staff, and maximize patient compliance. Oncology pharmacists play a vital role on the healthcare team by ensuring optimal medication regimens for cancer patients, educating patients, and monitoring patients for side effects during chemotherapy treatment.
Pharmacogenomic presentation medication saftey 110417 final2
This document outlines a study on the influence of pharmacogenomics on drug therapy and personalized medicine. The study focused on analyzing gene polymorphisms related to thyroid function in the Saudi population and their association with thyroid cancer risk and thyroxine drug dose requirements. The study found several novel and common single nucleotide polymorphisms in genes like DIO1, DIO3, PAX8, TSHB, and NIS. Some of these gene variants were associated with increased thyroid cancer risk. Additionally, polymorphisms in DIO1, PAX8 and TSHB were found to predict differences in required thyroxine drug doses for patients.
Personalized medicine in pediatric cancer
The maturation of genomic technologies has enabled new
discoveries in disease pathogenesis as well as new approaches to patient care.
In pediatric oncology, patients may now receive individualized genomic analysis to identify molecular aberrations of relevance for diagnosis and/or treatment.
Several recent clinical studies have begun to explore the feasibility and utility of genomics-driven precision medicine.
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Tumor conferences are multidisciplinary meetings at which the
management of cancer patients is discussed. They have been
an integral part of oncology services and are regarded
as an essential component of quality control and continuing
medical education. There are data to suggest that the tumor conference enhances patient care. Many studies of effectiveness have been conducted. Reported benefits include improved patient management and treatment. In this presentation, I'll try to assess the role of the multidisciplinary tumor conference in patient management in gynecologic oncology services.
Use of complementary and alternative medicine by cancer patients at the Unive...
CAM use is common among cancer patients in Nigeria. Most users do not obtain the
expected benefits, and adverse events are not uncommon. Every clinician in the field of oncology
should ask his/her patients about the use of CAM; this knowledge will enable them to better
counsel the patients
CV
Robert C. Shepard has extensive experience in cancer research and clinical oncology spanning over 40 years. He received his MD from Duke University and has held academic and clinical positions at several prestigious institutions. Currently, he works as a consultant in oncology drug development and clinical trials. He has led numerous clinical trials for both pharmaceutical and biotech companies and has published extensively in peer-reviewed journals. His expertise includes all phases of clinical trial design and implementation.
Imaging After Breast Cancer
This document discusses various breast imaging modalities for screening and diagnosis of breast cancer. It provides an overview of mammography, digital breast tomosynthesis, ultrasound, MRI, and molecular breast imaging. Mammography remains the primary screening tool, though its sensitivity decreases with breast density. Digital breast tomosynthesis has been shown to improve cancer detection rates compared to digital mammography alone. Ultrasound is useful as an adjunct but has high false positive rates for screening. MRI is recommended for screening high risk patients due to its high sensitivity. Molecular breast imaging is a potential adjunct screening tool for dense breasts that may help increase cancer detection over mammography alone.
Yehlaingbwar
This document discusses prognostic factors in epithelial ovarian cancer. It analyzes data from 55 patients treated with primary surgery and chemotherapy between 2005-2009. The key findings are:
1. Significant prognostic factors in univariate analysis included age, histology, FIGO stage, and ascites.
2. Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time. Patients with endometrioid or clear cell histology had longer survival, at 51 months.
3. Subgroups like endometrioid/clear cell histology, FIGO stage II, and those with ascites were also significant prognostic factors in univariate analysis.
Yehlaingbwar
This document summarizes a study on prognostic factors for epithelial ovarian cancer. The study analyzed 55 patients treated with surgery and chemotherapy between 2005-2009. Key findings included:
1) Significant prognostic factors in univariate analysis were age, histology, FIGO stage, and ascites.
2) Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time.
3) Patients with endometrioid or clear cell histology had longer survival times at 51 months.
feasibility study
This study proposes implementing a nutrition education program in Poudre School District that incorporates gardening and cooking lessons. The study analyzes the program's feasibility based on student interest, teacher acceptance, health impact, and financial impact. Student interest was high based on participation in similar programs. However, teacher acceptance was mixed - while teachers supported nutrition education, they felt unable to implement interactive programs due to preparation time requirements. The health impact was inconclusive as long-term studies have not been done, but short-term studies found improved nutrition knowledge and healthier food choices. The financial feasibility would depend on fitting costs such as staff and supplies within the school district's budget.
Personalized Medicine in Oncology
This talk covers the evolution of chemotherapy and the efforts that resulted in the discovery of targeted therapies.
Cancer in pregnancy
Cancer diagnosed during pregnancy most commonly includes breast cancer, lymphoma, and leukemia. Chemotherapy can be used during the second and third trimesters with acceptable risks of fetal complications including low birth weight and prematurity. The first trimester poses the highest risk of teratogenesis from chemotherapy. Surgery is the primary treatment for breast cancer during pregnancy, while chemotherapy and hormone therapy are also options depending on the trimester. Targeted therapies like trastuzumab carry risks of complications in later trimesters and are generally avoided during pregnancy.
Gastroenterology Research and Practice Jan16
1. The study analyzed treatment patterns over time in patients receiving first-line chemotherapy for advanced or metastatic esophageal or gastric cancer based on data from 2,808 patients documented in Therapiemonitor from 2006-2013.
2. Treatment intensity increased over time, with 49.3% of patients receiving triplet chemotherapy in 2013 compared to just 10.1% in 2006. HER2 testing rates increased from 49.1% in earlier studies to 79.1% in 2012-2013, though testing was still not always performed according to guidelines.
3. Usage of fluoropyrimidine/cisplatin combinations with trastuzumab declined from 67% in 2010-2011 to 50% in 2012-2013
Translation of Orphan DiseaseTrial Design into General Drug Development
Talk given at the 25th Anniversary Celebration of the Chinese University of Hong Kong School of Pharmacy
The Role of Surgery in Metastatic Breast Cancer (MBC)
This document summarizes evidence on the role of surgery for metastatic breast cancer (MBC). It finds that palliative surgery effectively controls symptoms for MBC patients. Prospective studies also suggest surgery may improve survival for responsive MBC patients with a limited number of metastases, especially those with ER+ disease. However, randomized trials yield mixed results on survival benefits. While definitive local therapy may be justified for select asymptomatic MBC patients, systemic therapy and targeted therapies remain the top priority for these patients overall.
Miami Breast Cancer Conference: Opioid-Sparing ERAS in Breast Surgery K Rojas MD
Presenting the #MaimoBreastTeam Opioid-Sparing Breast Surgery ERAS Protocols: Surgeons have the opportunity to make a massive impact in the opioid crisis by minimizing superfluous opioid prescribing after surgery. Shown here are the practical aspects of opioid-minimization so you can bring these lumpectomy and mastectomy protocols to your own institution.
Pharmacoepidemiology
Pharmacoepidemiology is defined as the study of drug use and effects in large populations. It bridges clinical pharmacology and epidemiology. Observational studies in pharmacoepidemiology include case reports, case series, trend analyses, cross-sectional studies, and cohort studies. These studies can provide information on patterns of drug use, risks and benefits of drugs, and evaluate specific drug use in certain conditions. Pharmacoepidemiological research informs government agencies, healthcare professionals, the pharmaceutical industry, academics, attorneys, consumers and patients.
Cancer pain
This document summarizes the results of a survey of 115 Japanese medical facilities that treat gynecologic cancers, regarding their palliative care practices. The survey found that about 30% of facilities had a dedicated palliative care ward. Most facilities had a palliative care team but about half of physicians on the team had other duties as well. End-of-life care was typically managed in the gynecology department. The median time between a patient's last chemotherapy treatment and death was 85 days. Over 15% of patients received chemotherapy within 30 days of death and over 7% within 14 days of death. The survey identified some gaps in palliative care coordination and opportunities to improve symptom management at the end of life.
Dr. Obumneke Amadi-Onuoha Scripts-19
Dr. Obumneke Amadi-Onuoha proposes a study to investigate whether genetic variants of the CYP2D6 gene, which encodes an enzyme involved in metabolizing opioids, influences risk of developing postoperative opioid dependence. The study would genotype patients undergoing laparoscopic cholecystectomy for CYP2D6 and monitor opioid prescriptions over one year, comparing genetic variations to addiction outcomes. Previous research found 5.9-3.1% of postoperative patients developed dependence, but opioid metabolism varies genetically. The hypothesis is that poor metabolizer CYP2D6 variants increase addiction risk versus ultra-rapid metabolizers.
Healthy Living After A Breast Cancer Diagnosis
Research increasingly shows that “energy balance” is important in breast cancer. Learn why exercise, weight, and diet are important for breast cancer patients.
DDI studies in humans
Focus of this presentation is Different types of drug drug interaction studies in Humans with examples and FDA guidance for industry for such studies.
A study on traditional, complementary and alternative medicine (tcam) usage a...
A study on traditional, complementary and alternative medicine (TCAM) usage among malaysian cancer patients
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Dana-Farber Cancer Institute
An overview of research for young women with breast cancer. By
Shoshana Rosenberg, ScD and Ann H. Partridge, MD MPH
Dana-Farber Cancer InstituteMeta analysis on her2 negative locally recurrent and metastatic breast cancer
Meta analysis on her2 negative locally recurrent and metastatic breast cancerMary Ondinee Manalo Igot
Bevacizumab in Her2neu Negative Locally Recurrent and Metastatic Breast Cancer: The BHERN Review
https://www.actamedicaphilippina.org/issue/1102Clinical Pharmacy Practice - Thao's presentation
The document discusses clinical pharmacy practice and pharmacy education in the United States. It provides an overview of postgraduate pharmacy residency programs including PGY1 and PGY2 residencies. It also describes the structure and requirements of pharmacy school including admission standards, accreditation, and typical career paths upon graduation such as community pharmacy, hospital pharmacy, or pursuing further training.
National onco venture_introduction_2017_march_v33
National OncoVenture (NOV) is a Korean government funded oncology drug development program. We are focusing on non-clinical and early stage clinical development of promising oncology drug candidates. These candidates are provided by researchers in academics, research institutes, biotech and pharmaceutical companies. We are co-developing the compounds with the originators through a virtual development model. The majority of the development activities are outsourced to domestic and global CRO/CMOs as well as specialized laboratories throughout the world. During the pre-clinical and clinical development, we aim to improve the value of our candidates by out-licensing our development programs to global pharmaceutical companies who can develop them further for the global market.
Newly Diagnosed, Stephanie Wethington, MD
This document outlines the process from diagnosis to follow-up care for ovarian cancer. It begins with an introduction and disclosure section. It then covers the diagnosis process, including symptoms, imaging, biopsy and surgery. Treatment options like surgery, chemotherapy, targeted therapy and clinical trials are discussed. The roles of the treatment team members are defined. Follow-up care including exams, imaging and survivorship are also summarized. Resources and questions from patients are addressed. Key terminology around histology, grade, stage and tumor markers is explained.
More Related Content
What's hot
CV
Robert C. Shepard has extensive experience in cancer research and clinical oncology spanning over 40 years. He received his MD from Duke University and has held academic and clinical positions at several prestigious institutions. Currently, he works as a consultant in oncology drug development and clinical trials. He has led numerous clinical trials for both pharmaceutical and biotech companies and has published extensively in peer-reviewed journals. His expertise includes all phases of clinical trial design and implementation.
Imaging After Breast Cancer
This document discusses various breast imaging modalities for screening and diagnosis of breast cancer. It provides an overview of mammography, digital breast tomosynthesis, ultrasound, MRI, and molecular breast imaging. Mammography remains the primary screening tool, though its sensitivity decreases with breast density. Digital breast tomosynthesis has been shown to improve cancer detection rates compared to digital mammography alone. Ultrasound is useful as an adjunct but has high false positive rates for screening. MRI is recommended for screening high risk patients due to its high sensitivity. Molecular breast imaging is a potential adjunct screening tool for dense breasts that may help increase cancer detection over mammography alone.
Yehlaingbwar
This document discusses prognostic factors in epithelial ovarian cancer. It analyzes data from 55 patients treated with primary surgery and chemotherapy between 2005-2009. The key findings are:
1. Significant prognostic factors in univariate analysis included age, histology, FIGO stage, and ascites.
2. Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time. Patients with endometrioid or clear cell histology had longer survival, at 51 months.
3. Subgroups like endometrioid/clear cell histology, FIGO stage II, and those with ascites were also significant prognostic factors in univariate analysis.
Yehlaingbwar
This document summarizes a study on prognostic factors for epithelial ovarian cancer. The study analyzed 55 patients treated with surgery and chemotherapy between 2005-2009. Key findings included:
1) Significant prognostic factors in univariate analysis were age, histology, FIGO stage, and ascites.
2) Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time.
3) Patients with endometrioid or clear cell histology had longer survival times at 51 months.
feasibility study
This study proposes implementing a nutrition education program in Poudre School District that incorporates gardening and cooking lessons. The study analyzes the program's feasibility based on student interest, teacher acceptance, health impact, and financial impact. Student interest was high based on participation in similar programs. However, teacher acceptance was mixed - while teachers supported nutrition education, they felt unable to implement interactive programs due to preparation time requirements. The health impact was inconclusive as long-term studies have not been done, but short-term studies found improved nutrition knowledge and healthier food choices. The financial feasibility would depend on fitting costs such as staff and supplies within the school district's budget.
Personalized Medicine in Oncology
This talk covers the evolution of chemotherapy and the efforts that resulted in the discovery of targeted therapies.
Cancer in pregnancy
Cancer diagnosed during pregnancy most commonly includes breast cancer, lymphoma, and leukemia. Chemotherapy can be used during the second and third trimesters with acceptable risks of fetal complications including low birth weight and prematurity. The first trimester poses the highest risk of teratogenesis from chemotherapy. Surgery is the primary treatment for breast cancer during pregnancy, while chemotherapy and hormone therapy are also options depending on the trimester. Targeted therapies like trastuzumab carry risks of complications in later trimesters and are generally avoided during pregnancy.
Gastroenterology Research and Practice Jan16
1. The study analyzed treatment patterns over time in patients receiving first-line chemotherapy for advanced or metastatic esophageal or gastric cancer based on data from 2,808 patients documented in Therapiemonitor from 2006-2013.
2. Treatment intensity increased over time, with 49.3% of patients receiving triplet chemotherapy in 2013 compared to just 10.1% in 2006. HER2 testing rates increased from 49.1% in earlier studies to 79.1% in 2012-2013, though testing was still not always performed according to guidelines.
3. Usage of fluoropyrimidine/cisplatin combinations with trastuzumab declined from 67% in 2010-2011 to 50% in 2012-2013
Translation of Orphan DiseaseTrial Design into General Drug Development
Talk given at the 25th Anniversary Celebration of the Chinese University of Hong Kong School of Pharmacy
The Role of Surgery in Metastatic Breast Cancer (MBC)
This document summarizes evidence on the role of surgery for metastatic breast cancer (MBC). It finds that palliative surgery effectively controls symptoms for MBC patients. Prospective studies also suggest surgery may improve survival for responsive MBC patients with a limited number of metastases, especially those with ER+ disease. However, randomized trials yield mixed results on survival benefits. While definitive local therapy may be justified for select asymptomatic MBC patients, systemic therapy and targeted therapies remain the top priority for these patients overall.
Miami Breast Cancer Conference: Opioid-Sparing ERAS in Breast Surgery K Rojas MD
Presenting the #MaimoBreastTeam Opioid-Sparing Breast Surgery ERAS Protocols: Surgeons have the opportunity to make a massive impact in the opioid crisis by minimizing superfluous opioid prescribing after surgery. Shown here are the practical aspects of opioid-minimization so you can bring these lumpectomy and mastectomy protocols to your own institution.
Pharmacoepidemiology
Pharmacoepidemiology is defined as the study of drug use and effects in large populations. It bridges clinical pharmacology and epidemiology. Observational studies in pharmacoepidemiology include case reports, case series, trend analyses, cross-sectional studies, and cohort studies. These studies can provide information on patterns of drug use, risks and benefits of drugs, and evaluate specific drug use in certain conditions. Pharmacoepidemiological research informs government agencies, healthcare professionals, the pharmaceutical industry, academics, attorneys, consumers and patients.
Cancer pain
This document summarizes the results of a survey of 115 Japanese medical facilities that treat gynecologic cancers, regarding their palliative care practices. The survey found that about 30% of facilities had a dedicated palliative care ward. Most facilities had a palliative care team but about half of physicians on the team had other duties as well. End-of-life care was typically managed in the gynecology department. The median time between a patient's last chemotherapy treatment and death was 85 days. Over 15% of patients received chemotherapy within 30 days of death and over 7% within 14 days of death. The survey identified some gaps in palliative care coordination and opportunities to improve symptom management at the end of life.
Dr. Obumneke Amadi-Onuoha Scripts-19
Dr. Obumneke Amadi-Onuoha proposes a study to investigate whether genetic variants of the CYP2D6 gene, which encodes an enzyme involved in metabolizing opioids, influences risk of developing postoperative opioid dependence. The study would genotype patients undergoing laparoscopic cholecystectomy for CYP2D6 and monitor opioid prescriptions over one year, comparing genetic variations to addiction outcomes. Previous research found 5.9-3.1% of postoperative patients developed dependence, but opioid metabolism varies genetically. The hypothesis is that poor metabolizer CYP2D6 variants increase addiction risk versus ultra-rapid metabolizers.
Healthy Living After A Breast Cancer Diagnosis
Research increasingly shows that “energy balance” is important in breast cancer. Learn why exercise, weight, and diet are important for breast cancer patients.
DDI studies in humans
Focus of this presentation is Different types of drug drug interaction studies in Humans with examples and FDA guidance for industry for such studies.
A study on traditional, complementary and alternative medicine (tcam) usage a...
A study on traditional, complementary and alternative medicine (TCAM) usage among malaysian cancer patients
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...Dana-Farber Cancer Institute
An overview of research for young women with breast cancer. By
Shoshana Rosenberg, ScD and Ann H. Partridge, MD MPH
Dana-Farber Cancer InstituteMeta analysis on her2 negative locally recurrent and metastatic breast cancer
Meta analysis on her2 negative locally recurrent and metastatic breast cancerMary Ondinee Manalo Igot
Bevacizumab in Her2neu Negative Locally Recurrent and Metastatic Breast Cancer: The BHERN Review
https://www.actamedicaphilippina.org/issue/1102What's hot (19)
Translation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug Development
The Role of Surgery in Metastatic Breast Cancer (MBC)
The Role of Surgery in Metastatic Breast Cancer (MBC)
Miami Breast Cancer Conference: Opioid-Sparing ERAS in Breast Surgery K Rojas MD
Miami Breast Cancer Conference: Opioid-Sparing ERAS in Breast Surgery K Rojas MD
A study on traditional, complementary and alternative medicine (tcam) usage a...
A study on traditional, complementary and alternative medicine (tcam) usage a...
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Research in the Program for Young Women with Breast Cancer: Past, Present and...
Meta analysis on her2 negative locally recurrent and metastatic breast cancer
Meta analysis on her2 negative locally recurrent and metastatic breast cancer
Similar to RhoChi Seminar Night - Oncology Pharmacy
Clinical Pharmacy Practice - Thao's presentation
The document discusses clinical pharmacy practice and pharmacy education in the United States. It provides an overview of postgraduate pharmacy residency programs including PGY1 and PGY2 residencies. It also describes the structure and requirements of pharmacy school including admission standards, accreditation, and typical career paths upon graduation such as community pharmacy, hospital pharmacy, or pursuing further training.
National onco venture_introduction_2017_march_v33
National OncoVenture (NOV) is a Korean government funded oncology drug development program. We are focusing on non-clinical and early stage clinical development of promising oncology drug candidates. These candidates are provided by researchers in academics, research institutes, biotech and pharmaceutical companies. We are co-developing the compounds with the originators through a virtual development model. The majority of the development activities are outsourced to domestic and global CRO/CMOs as well as specialized laboratories throughout the world. During the pre-clinical and clinical development, we aim to improve the value of our candidates by out-licensing our development programs to global pharmaceutical companies who can develop them further for the global market.
Newly Diagnosed, Stephanie Wethington, MD
This document outlines the process from diagnosis to follow-up care for ovarian cancer. It begins with an introduction and disclosure section. It then covers the diagnosis process, including symptoms, imaging, biopsy and surgery. Treatment options like surgery, chemotherapy, targeted therapy and clinical trials are discussed. The roles of the treatment team members are defined. Follow-up care including exams, imaging and survivorship are also summarized. Resources and questions from patients are addressed. Key terminology around histology, grade, stage and tumor markers is explained.
The 2nd Annual Oncology Asia
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
Studying drug induced-disease
Brian Strom discusses drug safety and the limitations of pre-marketing clinical trials in accurately detecting adverse drug reactions (ADRs). Post-marketing studies using pharmacoepidemiological methods are needed to further evaluate drug safety in large populations over long time periods. Pharmacoepidemiology applies epidemiological study designs like cohort studies and case-control studies to examine drug use and ADRs in real-world settings. However, drug safety research is challenging given issues like confounding factors, measurement of drug exposure, and potential conflicts of interest. Strom argues for increased focus on common ADRs rather than just rare events to better understand drug safety.
Career in Pharmacy
Is Pharmacy for you?
Check it out!
Want to Help People Get Well?
Like to Work Directly with Patients?
Enjoy a Wide Variety of Career Opportunities?
Want to be an Important Member of the Healthcare Team?
Excited to be a Part of Major Innovations in Drug Therapy?
Want to have a Job Mobility, Stability, and Flexibility?
If you want to be an instrumental character in improving patients' health by choosing the right medicines, then, this career is for you!
Have fun :)
POA for Hospital to achieve MDG 5
Plan of Action to Improve O&G Services at District Hospital Level to Achieve Millennium Development Goal 5.
Scope of Pharmacy in Pakistan
The document discusses the scope of pharmacy in Pakistan. It provides a brief history of pharmacy from ancient times to its establishment in Pakistan in 1863. It outlines the roles of the Pharmacy Council of Pakistan and describes the various career opportunities for pharmacists in areas like retail, hospitals, academia, research, management, quality control, and more. Overall, the scope of pharmacy is expanding in Pakistan with increasing opportunities across different healthcare sectors.
National onco venture_introduction_2017_june_v34
National OncoVenture, a system-integrated oncology drug development group, was established in June 2011. NOV is supported and located at the National Cancer Center of Ilsan. NOV is a national research and development project group of the Ministry of Health and Welfare.
Their purpose is to carry out the development of oncology drug candidates that were discovered by domestic pharmaceutical companies or academic institutes. NOV aims to develop the candidates into oncology drugs for the global market by providing significant drug development expertise.
National OncoVenture aspires to break through the bottleneck phenomenon in new drug development. Many academic research institutes and small biotechnology or pharmaceutical companies lack the resources to develop new drugs from the preclinical to clinical stage. We, as the non-originators, lead and support the development with experienced experts through an entire new drug development process.
NOV is the first governmental virtual drug development organization as an independent developer of new oncology drugs in South Korea. We select promising drug candidates from originators and lead joint-development projects of new drug candidates with originators utilized by outside networks. These external networks have the necessary know-how and experiences of new drug developments like CROs, CMOs, and consulting firms.
After completing the non-clinical and early clinical phase development, we license out the candidates or projects to domestic and overseas pharmaceutical companies. The profits are shared with the original candidate providers.
National OncoVenture provides consultations to the originators of drug candidates in need of knowledge, information, and experience for oncology market trends, drug candidates licensing, and various other processes.
The Role of RWE in Drug Development_4Jun2015_final
This document discusses how real-world evidence (RWE) can be incorporated earlier and more broadly in the drug development process. It proposes a revised model where RWE is used from early research through commercialization to inform target profiles, messaging on unmet needs, and clinical trial design. Specifically, it suggests using RWE to "stress test" enrollment projections and identify referral sources. The document also advocates for moving beyond observational research to conduct cluster-randomized real-world experiments addressing outcomes important to payers and patients like treatment patterns and costs.
The Development of Microbiome-based Probiotics in Prevention and Treatment of...
Presented at the 4th Microbiome R&D and Business Collaboration Forum: Europe. To find out more, visit: www.global-engage.com
Jisoo Pae, CEO of Genome and Company, discusses the development of novel therapeutics in obesity and cancer and gives an overview of their microbiome pipeline.
Career Presentation - PA
Physician assistants are nationally certified and state-licensed medical professionals who examine, diagnose, and treat patients under the supervision of physicians. They conduct physical exams, order tests, diagnose illnesses, set bones, prescribe medication, and assist in surgery. To become a PA requires a bachelor's degree, completion of a master's degree from an accredited PA program, passing a national certifying exam, and state licensure. Employment of PAs is projected to grow 30% by 2024 due to an increasing demand for primary care providers.
POA to Achieve MDG5
This document outlines a 2012 Plan of Action for hospitals in Sarawak to work towards achieving MDG 5, which aims to reduce maternal mortality. It provides statistics on maternal mortality rates in Sarawak and identifies key areas for improvement, such as ensuring adequate resources and staff training, improving emergency response and referral processes, enhancing antenatal and postnatal care, and promoting family planning services. The plan calls for various targets and activities to be implemented by hospital directors and obstetrics departments across Sarawak to help reduce preventable maternal deaths by 2015.
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
2014 Berlin_ Operational Excellence in Clinical Trails
The document summarizes an upcoming two-day conference on operational excellence in clinical trials taking place March 12-13, 2014 in Berlin, Germany. It outlines the conference agenda, topics, and speakers. Over 20 speakers are listed from pharmaceutical and clinical research organizations who will address topics like study feasibility, patient recruitment and retention, social media in recruitment, clinical project management, and conducting global clinical trials. The document provides an overview of the conference objectives, sessions, and opportunities for networking and discussion between professionals in clinical operations and research.
Responsibilities
A pharmacist is responsible for filling prescriptions, understanding thousands of drugs, counseling patients, planning drug therapy programs, and sometimes catching potentially deadly drug interactions. Becoming a pharmacist requires an undergraduate degree, completion of prerequisite courses, passing the PCAT exam, and admission to a Doctor of Pharmacy program. Pharmacy school tuition at public universities ranges from $3,000-20,500 per year for in-state residents or $14,800-82,000 for the 4-year program. After graduation, pharmacists find employment at hospitals, retail pharmacies, and other healthcare facilities.
Update on NC Pharmacy 2011
The document provides an update from the North Carolina Association of Pharmacists (NCAP) executive director on various pharmacy issues in 2011. It discusses the roles pharmacists should play in healthcare reform, such as in accountable care organizations and medical homes. It also addresses immunization expansion, medication adherence costs, and challenges to evolving pharmacy practice. Financial and membership data for NCAP from 2009-2010 is presented.
Practical guide to the U.S. physician office laboratory (POL) Part 1
This is part 1 of our white paper, it discusses what is a POL, history and trends, why POLs exist, and other introductory material.
All of the sections for this paper have a youtube video as well.
Intro to residencies 2010
This document provides an overview of pharmacy residency programs, including:
- Residency programs are becoming increasingly important for pharmacists to gain direct patient care experience and be eligible for board certification.
- Residencies allow pharmacists to build clinical skills through postgraduate training opportunities in various settings like hospitals, clinics, and retail pharmacies.
- The most common types of residencies are PGY-1 programs which provide a broad range of experiences, and PGY-2 programs which offer more specialized training.
- Obtaining a competitive residency position requires strong clinical skills, leadership experience, and networking at events like the ASHP Midyear meeting. Faculty at the University of Utah can provide guidance
2015_ashp_mcm_slides_final.pdf
This document discusses trends in pharmacy education and considerations for new faculty members pursuing an academic career. It notes that the majority of pharmacy faculty are on calendar year, full-time appointments and that pharmacy practice faculty now comprise over 50% of pharmacy school faculty. The document outlines expectations for teaching, research/scholarship, patient care, and service depending on tenure versus non-tenure track positions. It emphasizes showing evidence of one's accomplishments in these areas for promotion through activities like publishing, presenting, securing grants, and developing new educational programs.
Similar to RhoChi Seminar Night - Oncology Pharmacy (20)
The Role of RWE in Drug Development_4Jun2015_final
The Role of RWE in Drug Development_4Jun2015_final
The Development of Microbiome-based Probiotics in Prevention and Treatment of...
The Development of Microbiome-based Probiotics in Prevention and Treatment of...
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...
2014 Berlin_ Operational Excellence in Clinical Trails
2014 Berlin_ Operational Excellence in Clinical Trails
Practical guide to the U.S. physician office laboratory (POL) Part 1
Practical guide to the U.S. physician office laboratory (POL) Part 1
RhoChi Seminar Night - Oncology Pharmacy
- 1. Rho Chi Seminar Night Nova Southeastern University, College of Pharmacy April 1, 2016 Laura R. Bobolts, PharmD, BCOP Director, Oncology Pharmaceutical Affairs Oncology Analytics, Inc. Oncology pharmacy – sky’s the limit: A career path to consider for pharmacy students
- 2. • Almost everyone is touched by cancer • Pet • Friend • Self • Family member • I knew at an early age that I wanted to make a difference • Save families from the pain of losing a loved one to cancer Why Oncology Pharmacy ?!?
- 3. • Plan A: Biochemistry major to make the “magic bullet” • Plan A failed miserably! • Organic Chem lab was not my forte!!! Why Oncology Pharmacy ?!? Images from: http://www.huffingtonpost.co.uk/2014/01/03/chemistry-experiment-fails_n_4537127.html; http://www2.ljworld.com/photos/galleries/2007/jul/08 • Plan B: Become the pharmacist that ensures safe administration of chemo to the patient
- 4. Image from: http://www.hisuitestampa.com/business/moffitt.php • Graduated from Nova Southeastern University’s COP • PGY1 Residency at James A. Haley Veterans’ Hospital • Began oncology pharmacy career at Moffitt Cancer Center • Malignant Hematology • Women’s Oncology Clinic - Breast & Gynecologic Oncology • Established the role of a full-time clinical oncology pharmacist practicing in a solid tumor clinic • Transitioned to pediatric oncology Training Background…
- 5. • Director, Oncology Pharmaceutical Affairs • Manage a team of oncology pharmacists • Serve as the oncology medical information specialist • Oncology pharmacy benefits management • Review oncology-related drug authorization requests • Provide recommendations for anti-cancer therapy • Offer advise on national oncology-related drug policies • Review national drug fee schedules • Participate in the sales & marketing of the company My Current Role…
- 6. • Perform population-based research My Current Role…
- 7. • National oncology meeting presence is a must! My Current Role…
- 8. • In High Demand • Many different work settings • Inpatient hospital • Outpatient clinic or infusion center • Specialty pharmacy • Pharmaceutical company • Pharmacy benefits management Job Market for an Oncology Pharmacist
- 9. Bennett CL, et al. Lancet Oncol. 2014;15:e594-605 • Residency, residency … (PGY1 & PGY2 Oncology) • Board Certification in Oncology Pharmacy (BCOP) • Publication experience • Research experience What Employers Want?
- 10. Image from: http://www.bpsweb.org/about-bps/annual-reports/; Ignoffo R, et al. JOP; epub March 22, 2016 Job Market for an Oncology Pharmacist • As of 2014, only 1773 Board Certified Oncology Pharmacists (BCOP) • > 3000 BCOPs by 2020 ? • Requirements to take BCOP exam (either one) • ≥ 4 yrs practice w/ focus in oncology • PGY1 + ≥ 2 yrs practice w/ focus in oncology • PGY1 & Oncology PGY2
- 11. • Find your niche! • Pick your passion • Shadow in your prospective field • Set yourself apart from the crowd! • Treat all rotations like a job interview • Teach yourself, don’t wait to be taught • Get involved in projects that can lead to publications • Work on a 5-year plan, set goals • Strongly consider residency: PGY1 & PGY2 • Consider further even training: ?MBA Prepare Now…
- 12. Thank You! The Sky’s The Limit